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Background and purpose — Orthopedics and especially joint 
replacement surgery have had more than their fair share of 
unsuccessful innovations that have violated widely endorsed prin-
ciples for the introduction of new surgical innovations. We aimed 
to investigate (1) the trends in the use of the Birmingham Hip 
Resurfacing (BHR), the ASR hip resurfacing (ASR HRA) and the 
ASR XL total hip replacement (ASR XL THR) system with very 
different market approval processes and (2) whether their use 
was corroborated by clinical trials published in the peer-reviewed 
literature.
Methods — The literature was searched for any clinical stud-
ies that reported outcomes of the BHR, ASR HRA and ASR XL 
THRs. Data from 7 national hip arthroplasty registers were col-
lected and the number of annually implanted devices was matched 
to those reported in the literature.
Results — The cumulative number of implanted and pub-
lished BHRs grew proportionally with a small lag. The growth of 
implanted BHRs started to decline at the same time as the ASR 
HR was introduced. With regard to ASR HRAs, the cumulative 
proportion of implanted hips and those included in the published 
studies grew disproportionately after the introduction of the ASR 
in 2003. For ASR XL THRs, the disproportionality is even higher. 
Interpretation — The adoption of ASR hip replacements did 
not follow the proposed stepwise introduction of orthopedic 
implants. The adoption and use of any new implant should follow 
a strict guideline and algorithm even if the theoretical basis or the 
results of preclinical studies are excellent.
■
The very foundation of current health care management is to 
have a robust, evidence-based approach. The IDEAL Collabo-
ration (Idea, Development, Exploration, Assessment, Long-
term follow-up) proposes that such an approach is character-
ized by: “the promotion of unbiased, highly reliable types of 
evidence” (Barkun et al. 2009). A pragmatic approach taken 
by Haynes (1999) states that any innovation should work 
under ideal circumstances (“Can it work?”) as well as the 
usual circumstances (“Does it work in practice?”). Unfortu-
nately, orthopedics and especially the fi eld of joint replace-
ment surgery have had more than their fair share of unsuccess-
ful innovations that have violated these principles. 
A detailed stepwise algorithm for the introduction of new 
orthopedic implants was established by Malchau (Malchau 
2000, Malchau et al. 2011). All new implants should go 
through a rigorous 4-step introduction process: preclinical 
step and clinical steps 1–3. The preclinical step includes pre-
clinical testing, i.e., in hip simulators (“Can it work?”). Very 
similar guidelines related to the catastrophic failure of the 3M 
Capital Cemented Hip System in England in the 1990s were 
outlined by the Royal College of Surgeons of England (RCS) 
(2001). 
In the early 2000s, the Food and Drug Administration 
(FDA) in the United States exempted new devices from clini-
cal trials if manufacturers could prove similarity to another 
product already on the market (Cohen 2012, Day et al. 2016). 
In the European Union, a similar protocol was followed which 
granted approval (CE label) for any metal-on-metal (MoM) 
hip implant as long as the manufacturer was able to show simi-
larity to a product already on the market (Cohen 2012). Due to 
the similarity between the two approval procedures, in many 
cases the introduction of MoM implants in the United States 
and the European Union failed to meet any of the Clinical Step 
1 processes outlined by Malchau et al. (2011), namely, open 
prospective studies (usual circumstances, “Does it work?”). 
The Articular Surface Replacement (ASR) MoM hip resurfac-
ing (HR) system and the ASR XL total hip replacement (THR) 
implant (Depuy Orthopaedics, Warsaw, IN), both of which led 
to catastrophic results, and many other hip resurfacing and 
large-diameter MoM THR designs were introduced claim-
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ing similarity to other MoM implants or their characteristics 
already on the market (U.S. FDA 2005, 2008). In contrast, 
the Birmingham Hip Resurfacing (BHR, Smith & Nephew, 
Warsaw, IN) system and the Conserve+ (Wright, Memphis, 
TN) implant were the fi rst second-generation MoM hip resur-
facing designs on the market to undergo thorough preclinical 
and clinical testing (U.S. FDA 2006a, 2006b). 
Our main hypothesis is that the ASR hip replacement system 
was adopted into use far too rapidly and lacked the support of 
clinical results from published studies in the peer-reviewed 
literature. Hence, in this paper we aim to investigate (1) the 
trends in the use of the BHR and ASR hip replacements and 
(2) whether their use was corroborated by clinical trials pub-
lished in the peer-reviewed literature. 
Materials and methods
The MoM hip replacement brands investigated
3 different MoM hip arthroplasty brands were investigated: the 
BHR implant, the ASR HRA and the ASR XL THR implants. 
Identifi cation of studies
We searched for clinical studies in the PubMed and Scopus 
databases. The search strategies and the PRISMA fl ow chart 
of the study selection are shown in Supplementary data, fi les 
1–3.
Inclusion and exclusion criteria
A study was eligible if (1) it included an original patient cohort 
operated on with either the BHR, ASR HRA or ASR XL THR 
implants and, (2) the study clearly reported survival rate, revi-
sion rate or a failure rate. We defi ned an original patient cohort 
as a population of patients followed for a disclosed period and 
primarily operated on with a certain implant within a certain 
time interval at a disclosed hospital(s). If more than 1 implant 
was used and the number of patients for each implant was 
not given, the study was excluded. Furthermore, a study was 
excluded if (1) it included patients referred from somewhere 
other than the hospital(s) where the study was carried out (vio-
lation of eligibility criteria 1), or (2) more than 1 implant was 
used but the revisions were not stratifi ed by the implant. 
If a study included a study arm or a subcohort of a study 
arm that had been included in a previous study with differ-
ent follow-up periods, both studies were included since these 
were considered separate reports.
All the records retrieved from the 2 databases using our 
search strategy were screened. The screening of abstracts was 
done by two of the authors (AR and LL). All studies that out-
lined the use of any MoM hip implant or a hip implant under a 
brand name along with any clinical outcome (patient-reported 
outcome score, survival rate, failure rate, complication rate, 
revision rate, deaths, metal ion levels, cross-sectional imag-
ing fi ndings) were selected for full-text review and eligibility 
assessment. Retrieval and eligibility assessment was done by 
the fi rst author (AR). 
Data extraction
No detailed data extraction was carried out. The only data 
recorded were the number of hips included, the publication 
year and the type of implant used.
Registry data
Data were collected from the Australian Orthopaedic Asso-
ciation National Joint Replacement Registry (AOANJRR), 
the National Joint Registry for England and Wales (NJR), 
the Swedish Hip Arthroplasty Register (SHAR), the Finnish 
Arthroplasty Register (FAR), the New Zealand Joint Registry 
(NZJR), the Danish Hip Arthroplasty Register (DHR) and the 
Norwegian Arthroplasty Register (NAR). The annual reports 
available in the websites of respective registries were screened 
and the numbers of BHR, ASR hip resurfacings and ASR XL 
THR annually implanted were recorded. Data from the FAR 
were retrieved directly. 
Full historical data on the use of the BHR were available 
from the AOANJRR, SHAR, FAR, NZJR, DHR and NAR. 
The annual report of the NJR was fi rst published in 2004. 
Therefore, data on the annual number of implanted BHRs in 
England and Wales between 1997 and 2002 were lacking. Full 
historical data on the use of the ASR hip replacements was 
available from all 7 registries.
Statistics
Data from published studies and registries were collected yearly 
ending in 2013. Since ASR hip replacements were recalled by 
the manufacturer in September 2010 and their use halted in 
2011 at the latest, further data collection was not deemed fea-
sible. The annual increase in both the implanted hips reported 
in the registries and the increase in the hips included in the 
published clinical studies were calculated. For each year, a 
running cumulative proportion of implanted and reported hips 
was calculated. This was achieved by dividing the cumulative 
number of implanted and reported hips in each year by the total 
cumulative number in the year 2013. Following this, the pro-
portion of both implanted and reported hips was 1.0 in 2013 
and smaller in the preceding years. The primary variable of 
interest was a time series consisting of cumulative number of 
implanted and reported hips as described above. 
Results
89 studies were identifi ed. The details of all studies included 
are listed in Supplement 4. In the AOANJRR, NJR, FAR and 
DHR, the growth in implanted BHRs started to decline at the 
time the ASR HRA was fi rst introduced. Moreover, the use of 
the BHR peaked 1 to 2 years prior to the peak in use of the 
ASR HRA (Figure 1). 
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The trend in the use of the BHR was similar across AOAN-
JRR, NJR, SHAR and FAR (Figure 2). In the 3 other regis-
tries variable patterns were seen. The proportion of other HR 
designs, especially the ASR HRA, increased rapidly from 
2004. However, in 2010 the proportion of BHRs started to rise 
and the use of ASR came to an end due to the recall in Sep-
tember 2010.
In the studies that reported the results of the 3 implants, the 
number of hips included in the studies varied greatly from 
year to year (Supplementary data fi le 5).
Figure 3 shows the relative proportion of reported and 
implanted hips annually. In 2013, both cumulative propor-
tions reached 100% or a ratio of 1.0 (see Figure 3). With the 
BHRs, a steady growth in the hips included in the published 
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Figure 1. Annual implanted 
Birmingham Hip Resurfac-
ings (BHR), Articular Surface 
Replacement hip resurfacings 
(ASR HRA) and ASR XL total 
hip arthroplasties (ASR XL) in 7 
registries between 1999–2013: 
NJR, AOANJR, SHAR, FAR,) 
NZJR, NHR, and DHR.
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Figure 2. Yearly proportion of 
HRA brands in the registries: 
NJR, AOANJR, SHAR, FAR, 
NZJR, NHR, and DHR. 
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studies was seen, but in 2007 a rapid increase occurs which 
matches the overall growth in implanted hips. With regard 
to ASR HRAs and ASR XL THRs, the cumulative propor-
tions of implanted hips and those included in the published 
studies grew disproportionately after the introduction of the 
ASR in 2003. The fi rst study that included patients operated 
on with the ASR XL THR was published in 2010 (Lang-
ton et al. 2010). In the same year, the ASR hip system was 
recalled.
Discussion
An evidence-based approach to the introduction of surgical 
innovations is fundamental (Table 1) (Haynes 1999, Mal-
chau 2000, McCulloch et al. 2009). This is especially true for 
joint replacement surgery since “the probability of success of 
modern innovations is very low due to the long-term success 
enjoyed by contemporary THA”, as Malchau et al. (2011) 
stated, and as also stressed by the Balliol Collaboration behind 
the IDEAL guidelines (McCulloch et al. 2009). Unfortunately, 
the fi eld of joint replacement surgery has experienced very 
little success in achieving a rigorous stepwise introduction 
process (Nieuwenhuijse et al. 2014). The “3M disaster” struck 
the UK in 1990 (Royal College of Surgeons of England 2001). 
The 3M Capital Hip was intended to be similar to the Charn-
ley Hip with only slight modifi cations. These slight modifi ca-
tions had, however, a substantial adverse effect on the survival 
of the implant, and it was subsequently recalled. The current 
MoM disaster is the result of an identical series of catastrophic 
mistakes (Cohen 2011, 2012). The open prospective studies 
required in Clinical Steps 1 and 2 of the stepwise introduc-
tion of implants suggested by Malchau (2000) and the clinical 
trials in the RCS 2001 recommendation are the responsibility 
of individual surgeons. 
The FDA approved the BHR through premarket approval 
(PMA) (U.S. FDA 2006, 2009). The ASR XL THR, on the 
other hand, gained the 510(k) clearance that relies on “proof 
of similarity” and is most often obtained by non-clinical tests. 
Moreover, the 510(k) application must state that devices are 
substantially equivalent. In 2005, the FDA approved the “ASR 
Acetabular Cup system”, which introduced a MoM THR with 
femoral head sizes of 39 to 55 mm (U.S. FDA 2005). The 
predicate devices in the application, i.e., the devices with 
which similarity was claimed, were the Pinnacle MoM THR 
and the TRANSCEND MoM THR. Interestingly, the work 
by Ardaugh et al. (2013) shows that the ancestry of these 2 
devices goes as far back as the McKee–Farrar hip and Ring 
hip prostheses. As late as 2008, the FDA cleared an extension 
to the “ASR Acetabular Cup System”, namely the “ASR XL 
Acetabular System” that introduced femoral head sizes of 55 
to 63 mm. The “ASR Acetabular Cup System” was named as 
a predicate device along with the TRANSCEND MoM THR 
and the “ASR 300 Acetabular Cup system”, of which the latter 
had undergone no mechanical or clinical tests (U.S. FDA 
2007, Ardaugh et al. 2013). The ASR HRA was not, however, 
approved by the FDA. Interestingly, the ASR femoral head 
designed for use in hemiarthroplasty surgery was approved 
using the previous poorly survived TARA implant as the 
equivalent device. Controversially, although the ASR HRA 
was not approved by the FDA, it was granted a CE marking 
in the European Union (Cohen 2011, House of Commons Sci-
ence and Technology Committee 2012). 
Basically, a conceptual model of a healthy adoption of an 
innovation is a bell-shaped curve when the potential market 
share is depicted as described in “Diffusion of Innovations” 
by Rogers in 1962 and which was also co-adopted in surgical 
innovations by Wilson (2006). The adoption of the ASR XL 
THA in some registers was clearly too fast, and in some regis-
ters the adoption phase can even be considered to be missing. 
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Figure 3. Annual cumulative proportion (brown lines) of implanted Birmingham Hip Resurfacings (BHR), Articular Surface Replacement hip 
resurfacings (ASR), and ASR XL total hip arthroplasties (ASR XL) according to registries and annual cumulative number of hips reported in 
the peer-reviewed literature (red lines), i.e., when 50% of the total cumulative number of BHRs were implanted in 2006, approximately 10% of 
all patients included in the peer-reviewed studies were available in the literature, when 90% of the total cumulative number of ASR HRAs were 
implanted in 2008, approximately 10% of all patients included in the peer-reviewed studies were available in the literature, and when 95% of the 
total cumulative number of ASR XL THAs were implanted in 2008, approximately 0% of all patients included in the peer-reviewed studies were 
available in the literature.
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This is most likely due to the marketing psychology, as large-
diameter MoM THRs were marketed as being identical to the 
BHR and other well-functioning HRs, and hence the adop-
tion would not have been a problem. Moreover, large-diameter 
bearings with a stem were seen as ideal for reducing disloca-
tion rate, and thus they were easily adopted for those patients 
unsuitable for hip resurfacing. Clearly, this was a disastrous 
phase as the hip simulator studies did not reveal the in vivo 
effects of increased modularity (taper–trunnion interface) and 
subsequent wear (Matthies et al. 2013). 
The use of the BHR decreased quickly after the introduc-
tion of the ASR HRA. Moreover, there was a clear shift in the 
use of the hip resurfacing concept away from the BHR, with 
numerous studies available at the time, to other HR designs, 
mainly ASR. The adoption of the ASR hip resurfacing device 
was quite rapid. Again, this was most likely an industry-
driven change since the similarity between the 2 was heavily 
emphasized, and because similarity was also a crucial step in 
the approval process. Yet again, this was a disastrous phase 
as the hip simulator studies did not reveal the in vivo effects 
of reduced clearance and especially the reduced cup hemi-
sphericity on the wear of the bearing couple in the ASR hip 
(Underwood et al. 2012, Matthies et al. 2014). 
The IDEAL guidelines state that after the fi rst stage (“Idea”) 
comes stage 2a (“Development”). The collaboration behind 
the IDEAL guidelines demands that “prospective develop-
ment studies” are performed in stage 2a (Table 1). This can be 
considered equal to the demand for open prospective studies 
proposed by Malchau (2000, 2011). Clearly, phase 2a in the 
IDEAL guidelines and the fi rst clinical step in the Malchau 
algorithm was too rapid or even lacking during the shift from 
the BHR to other HR designs, especially ASR HRA.  
When data from the registries and from the literature are 
combined, obvious conclusions can be drawn. In an optimal 
situation, the number of studies and patients included would 
match how much the current innovation is used. The assump-
tion is that as the adoption of an innovation spreads, the more 
people are likely to report the results of the innovations. 
However, after a certain level of adoption and spreading, a 
continuous fl ow of studies is not needed since the results will 
most likely be the same. With the BHR there was a suffi cient 
number of studies that included adequate numbers of patients 
Table 1. Comparison and suggested equality of 3 different recommendations related to introduction of orthopedic innovations
Stepwise introduction of new implant technology Evaluation and stages of surgical Recommendations about the design and  
 innovations clinical evaluation of hip prosthesis
Initial step = preclinical testing Stages 0–1 = Innovation Phase I = Preclinical trials
“…the preclinical testing might increase both  “pre-human work and development” “Full evaluation requires thorough pre-clinical
the effi cacy and the safety of the innovation,…” “Single digit, highly selected patients” trials, e.g., by radio-stereometric analysis of
  “patient safety can often be improved  stem migration,…”
  through iterative animal studies, use of 
  simulators or augmented reality”
Clinical step 1 = 
Prospective randomized studies Stage 2a = Development Phase II = Clinical trials
“open prospective and preferably randomized  “attempts to replicate reliably early “Ideally, randomized controlled trials should be
trial that includes a minimum of patients but  results should be made” carried out to evaluate the performance of
yields a relevant evaluation”   prostheses used for total hip replacement.”
“Results from this fi rst step determine whether 
further clinical evaluation is worthwhile”
  Stage 2b =  
Clinical step 2 = Multicenter studies Early dispersion and exploration 
“exposing the new procedure to a broader  “enough reports have been published for
aspect in the orthopaedic community” the technology to be generally regarded 
 as safe and it is starting to lose its 
 experimental character”
 
 Stage 3 = Assessment 
 “The procedure is now part of many 
 surgeons’ practices “
 “results have not been described in 
 previously excluded groups”
 
 Stage 4 = Long-term implementation
Clinical step 3 = Register studies and monitoring Phase III = Post-marketing surveillance
“to include a continuous control group by  “surgeons to monitor late or rare “Three alternatives currently exist:
using register studies based on large cohorts  outcomes” (a) a registry; (b) post-market clinical trials;
to reveal early or unusual and potential   and (c) ad hoc analysis of adverse incidents
clinical catastrophic complications”  and user experience.”
  “It is therefore recommended that a national   
  hip registry should be established.”
11222 Reito D.indd   482 8/3/2017   2:28:32 PM
D
ow
nl
oa
de
d 
by
 [T
am
pe
re 
Un
ive
rsi
ty]
 at
 04
:58
 04
 O
cto
be
r 2
01
7 
Acta Orthopaedica 2017; 88 (5): 478–483 483
to provide evidence of its use following the years of introduc-
tion, at least in male patients. To sum up, in the case of BHR 
we postulate that there was causality between the registry and 
literature data meaning that the numbers reported in the regis-
try predicted the numbers reported in the literature. 
For the ASR hip replacement, there is basically no evidence 
supporting its use. The use of ASR hip resurfacing peaked in 
2007. Prior to 2007, only 1 study had been published (Siebel et 
al. 2006). The disproportionality and lack of causality between 
the actual use and the evidence is even more catastrophic with 
the ASR XL THR. The concept was adopted extremely quickly 
violating the IDEAL guidelines and the Malchau algorithm as 
there was no evidence in the peer-reviewed literature to sup-
port their use. Both implants show a clear delay or a lag and 
the lack of a steady fl ow of studies in the peer-reviewed litera-
ture following the introduction of the implants.
Our study is not without limitations. The use of the ASR was 
also evident in North America. Since we are lacking openly 
available registry data from the USA and Canada, the global 
trends cannot be directly inferred from our data. Second, indi-
vidual registries show some variation in the use of implants 
and hence the severity of the violation of the introduction pro-
cess varies between countries.
To conclude, the introduction of the ASR hip replacement 
violated the fundamental principles of adoption by an almost 
complete lack of studies in the peer-reviewed literature follow-
ing its introduction. The results obtained with hip simulators, 
the claims of similarity to or equivalence with other implants 
and theoretical advantages failed catastrophically to substitute 
for the most fundamental foundation of any innovation: the 
evidence in the literature. We should learn lessons from these 
recent mistakes made with hip replacements on a wider scale. 
The adoption and use of any new innovation should follow 
strict guidelines and algorithms even if the theoretical basis or 
the results of preclinical studies are excellent.
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